Evidence and challenges in MeVO and distal occlusions, what do we know in 2026?

Anatomical definitions and safety ceilings

Defining a MeVO or DiVO is complex. Standard inclusion criteria focus on location (like M2/M3 segments), but vessel diameter dictates safety.
A wave of recent distal trials failed due to two main factors:

• Medical efficacy: Intravenous lytics alone yield a 75% good outcome rate in M2 occlusions, setting a high bar for thrombectomy.
• Hemorrhagic risks: Tools oversized by more than 20% relative to the vessel diameter cause a threefold increase in symptomatic complications.

However, the Oriental MeVO trial emerged as a key positive outlier. This success is explained by a lower patient exposure to IV lytics (only 30% vs. 60-70% in negative trials) and a restriction to ultra-high-volume centers, which mitigated technical risks through operator experience.

Clinical guidelines for 2026

While awaiting large-scale recommendation changes, the daily clinical routine for MeVO interventions relies on strict technical adjustments:

• Patient selection: Prioritize young patients with disabling deficits who are ineligible for IV lytics.
• Procedural stability: Perform the intervention under general anesthesia to optimize precision.
• Low-profile tools: Exclusively select specialized small-vessel devices and 17 microcatheters.

Ultimately, the score is not yet settled. To bridge the gap between conflicting trial data, future research must focus on optimizing device safety profiles, understanding vessel diameter thresholds, and improving how we measure clinical success in daily patient lives.